🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Glioblastoma WHO Grade IV

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma NCT07416188Phase 1, Phase 21 site📍 Bethesda National Institute of Neurological Disorders and Stroke (NI… · Tests: LMP744, Conventional Surgery or Biopsy A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) NCT04573140Phase 12 sites📍 Washington D.C.📍 Gainesville University of Florida · Tests: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP li… Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma NCT06410248Phase 11 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours NCT06630260Phase 1, Phase 23 sites📍 Cambridge📍 Sutton📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Avutometinib, Defactinib, Temozolomide TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma NCT07862647Phase 11 site📍 Buffalo Alpheus Medical, Inc. · Tests: 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound Clinical Trial of BMS-986504 in Recurrent GBM Patients NCT06883747EARLY Phase 11 site📍 Phoenix Nader Sanai · Tests: BMS-986504 Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression NCT05565118Phase 11 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Standard Surgical Treatment, Intraoperative Electrocorticography Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma NCT07100730Phase 39 sites📍 Gold Coast📍 Melbourne📍 Perth Telix Pharmaceuticals (Innovations) Pty Limited · Tests: TLX-101-Tx + Lomustine, TLX101-Tx Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253Phase 220 sites📍 Aurora📍 Washington D.C.📍 Chicago Nationwide Children's Hospital · Tests: Ribociclib, Everolimus, Temozolomide (TMZ) Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme NCT05423210EARLY Phase 11 site📍 Stony Brook Stony Brook University · Tests: Atezolizumab + FSRT radiation Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma NCT07648823EARLY Phase 12 sites📍 Beijing📍 Beijing Beijing Tiantan Hospital · Tests: [177Lu]Lu-XT771 UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 NCT07459101NA1 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Dose painting + Reduced Margins Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment NCT05460507Phase 11 site📍 San Antonio Cerenome · Tests: Retreatment Rhenium Liposome Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion NCT06333899EARLY Phase 118 sites📍 Aurora📍 Washington D.C.📍 Chicago Nationwide Children's Hospital · Tests: Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) NCT06118723n/a8 sites📍 San Francisco📍 Boston📍 Leuven Jasper Gerritsen · Tests: Supramaximal resection, Maximal safe resection Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy NCT05789394Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy, Magnetic Resonance Imaging, Omma… Implantable Microdevice In Primary Brain Tumors NCT04135807EARLY Phase 11 site📍 Boston Oliver Jonas · Tests: Microdevice ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial NCT07089641Phase 12 sites📍 Los Angeles📍 New York Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma NCT07560865Phase 11 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4) NCT07488754NA2 sites📍 Warsaw📍 Warsaw Medical University of Warsaw · Tests: Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques NCT06623565NA1 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: Multimodal image-guided resection Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma NCT07091864NA3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Best Practice, Biospecimen Collection, Dietary Intervention, Glucose Measurement, Magnetic Resonance Imaging Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma NCT06934889Phase 111 sites📍 Los Angeles📍 Miami📍 Indianapolis Memorial Sloan Kettering Cancer Center · Tests: ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy BC008-1A Injection for Recurrent CNS WHO G4 Glioma NCT06773481Phase 11 site📍 Beijing Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Tests: BC008-1A, BC008-1A Targeted Pediatric High-Grade Glioma Therapy NCT05839379n/a22 sites📍 Aurora📍 Washington D.C.📍 Miami Nationwide Children's Hospital SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) NCT05303519Phase 361 sites📍 Birmingham📍 Phoenix📍 Phoenix Nuvation Bio Inc. · Tests: safusidenib, Placebo Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) NCT01906385Phase 1, Phase 24 sites📍 Manhasset📍 Columbus📍 Dallas Cerenome · Tests: Rhenium Liposome Treatment Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma NCT06160206Phase 23 sites📍 Scottsdale📍 Jacksonville📍 Rochester Academic and Community Cancer Research United · Tests: Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation T… The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. NCT03861299NA5 sites📍 Ghent📍 Tilburg📍 Rotterdam Jasper Gerritsen · Tests: Awake craniotomy, Craniotomy under general anesthesia A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma NCT05765812Phase 1, Phase 216 sites📍 Chicago📍 New York📍 New York Debiopharm International SA · Tests: Debio 0123, Temozolomide, Radiotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy